Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis.
Stage IV cutaneous T-cell lymphoma (CTCL) has a notoriously poor prognosis and many treatment options exist. We describe the successful treatment of a case of stage IV CTCL with combination photopheresis and high-dose interferon alfa (IFNalpha). The patient was treated with combination therapy of monthly photopheresis and daily doses of IFNalpha up to 36 MU. Response to therapy was followed by clinical observation and Southern blot analysis for the detection of a malignant clone. The findings of this case were compared with others using a computer-based literature review. A complete clinical response lasting 64 months was achieved. Clinical relapse was preceded by an increase in the CD4/CD8 ratio and by reappearance of the T-cell receptor gene rearrangement. Combined photopheresis and high-dose IFNalpha led to a durable and sustained complete response in stage IV CTCL. CD4/CD8 ratios and T-cell gene rearrangements may be helpful in patient management.
Haley
H R
HR
Department of Dermatology, University of Alabama at Birmingham, 35233, USA.
Davis
D A
DA
Sams
W M
WM
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016516:CD4-CD8 Ratio; D002999:Clone Cells / Q000276:immunology; D003131:Combined Modality Therapy; D015329:Gene Rearrangement, T-Lymphocyte; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008297:Male; D017893:Photopheresis; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy
D000970:Antineoplastic Agents; D016898:Interferon-alpha